T he lens consists of a proliferative epithelium that lines the anterior surface of the structure, covering the apical surface of a core of postmitotic terminally differentiated fiber cells. These two types of cells represent a single lineage, in that lens epithelial cells migrate toward the equatorial region of the lens where they exit the cell cycle and differentiate into fiber cells. Genetic engineering has emerged as a powerful tool for the investigation of the molecular basis of lens fiber differentiation. The mouse lens was one of the first tissues in which tissue-specific transgene expression was demonstrated 1 and was the first tissue in which Cre-mediated recombination was used to catalyze tissue-specific genomic engineering. 2 Most of the promoters used for transgene expression in the lens are derivations of crystallin promoters, and with the exception of the ␣B-crystallin promoter, [3] [4] [5] they are capable of driving highlevel transgene expression only in the lens fiber cells. 6 -13 To investigate mechanisms of fiber differentiation, however, it is desirable to manipulate gene expression in the undifferentiated lens epithelium.
Crystallins are major water-soluble cytoplasmic proteins in the lens. The ␣-, ␤-, and ␥-crystallins, found in all mammalian lenses, are expressed in either a lens-specific or a lens-preferred manner. The ␣-crystallins consist of ␣A-and ␣B-crystallin. The lens is the major site of ␣A-crystallin expression, where it is detected in both epithelial and fiber cells, but a dramatic increase in the expression of ␣A-crystallin occurs as the lens epithelial cells differentiate into lens fibers. 14 Only trace amounts of ␣A-crystallin have been detected in a small number of non-lens tissues. 15, 16 Multiple cis-acting transcriptional regulatory elements residing in the 5Ј-flanking region of the murine ␣A-crystallin gene contribute to its lens-preferred expression. [17] [18] [19] [20] [21] [22] In contrast, murine ␣B-crystallin is expressed in the lens, retinal pigment epithelium (RPE), heart, skeletal muscle, and brain. 3, [23] [24] [25] [26] [27] [28] A short fragment of the ␣B-crystallin promoter (Ϫ164/ϩ44), lacking upstream elements shown to be important for non-lens expression of ␣B-crystallin, [25] [26] [27] was shown to confer lens specificity in transgenic mice. 29 However, a later report demonstrated that this promoter is also active in the postnatal corneal epithelium. 5 Two regulatory elements within this region bind Pax6 and mediate transcriptional activation of the ␣B-crystallin gene in the lens epithelium. 4 Unlike ␣A-crystallin, ␣B-crystallin has more pronounced expression in the lens epithelium than in the fibers. 14 In the embryonic and adult lens, Pax6 mRNA is detected mainly in the epithelium. 30, 31 Although Pax6 protein is detectable in newly differentiated lens fibers, the protein is gradually lost as fiber differentiation proceeds. 30, 31 Pax6 plays many critical roles in early vertebrate eye development, and lens formation does not occur in the absence of Pax6. 32, 33 Pax6 plays a role in regulating the spatial and temporal expression of ␣A-, ␣B-, ␥E-, and ␥F-crystallins in the mouse; ␣A-, ␤B1-and ␦1-crystallins in chick, and -crystallin in the guinea pig. 4,17,31,34 -37 In addition, Pax6 has been shown to act upstream of transcription factors that are essential in lens development including Sox2, Six3, L-Maf, and Prox1. 32, 38, 39 An element from the Pax6 P0 promoter, known as the ectoderm enhancer, has been shown to direct transgene expression in the lens placode and placode-derived structures, such as the epithelium of the lens, cornea, conjunctiva, and lacrimal gland. 40, 41 Transgene expression with this enhancer is not maintained in lens fiber cells. Our purpose was to find or engineer promoters capable of driving transgene expression in the entire lens, including the lens epithelium, but without the inclusion of other ocular epithelia. We chose to use two different genes to evaluate the promoter expression pattern to control for possible influences of coding sequence on promoter activity. The first of these, human growth hormone (hGH), is not normally expressed in the eye, but can easily be detected by in situ hybridization or immunohistochemistry. The second gene was Cre recombinase. Cre is a P1 bacteriophage-derived DNA recombinase with a specific 34-bp recognition sequence called a loxP site. Cre recombinase was used to test these promoters with the thought that the resultant mice could not only provide more in vivo evidence about the effect of the Pax6 consensus binding site on the ␣A-crystallin promoter activity, but also could serve as tools to create conditional inactivation of genes in a tissue-specific manner.
Within the eye, transgenic constructs containing the murine Ϫ214/ϩ38 ␣B-crystallin promoter most often drove transgene expression in the lens epithelium and RPE, whereas constructs containing the native murine Ϫ282/ϩ43 ␣A-crystallin promoter most often drove transgene expression only in fiber cells of the lens. Insertion of a DNA sequence that binds Pax6 34 into the ␣A-crystallin promoter enhanced the expression of two different reporter genes in the lens epithelium while maintaining fiber cell expression.
METHODS

Construction of Transgenic Vectors
All primer sequences and detailed methods are available in the online appendix at www.iovs.org/cgi/content/full/45/6/1930/DC1. A novel BglII site was inserted into the CPV2 vector 42 at Ϫ86 relative to the murine ␣A-crystallin transcription start site by overlapping PCR, creating the intermediate CPV7 vector. A consensus Pax6 binding site, 34 created by annealing two partially complementary oligonucleotides with 5Ј overhangs compatible with the BglII restriction site, was inserted into the BglII site of CPV7 to generate CPV14 and CPV15 vectors, differing only by the orientation of the single Pax6 binding site. A genomic fragment containing the hGH gene from pOGH (obtained from Francesco DeMayo, Baylor College of Medicine, Houston, TX 43 ) was subcloned into CPV2, CPV14, and CPV15, creating CPV2/ hGH, CPV14/hGH, and CPV15/hGH, respectively.
To create the ␣B1/hGH construct, genomic sequence from Ϫ214 to ϩ38 of the mouse ␣B-crystallin gene (relative to the major lens transcription start site, GenBank accession no. M73741 44 ; http://www. ncbi.nlm.nih.gov/Genbank; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD) was amplified by PCR and inserted into CPV2, replacing the murine ␣A-crystallin promoter and creating the vector ␣B1. The promoter of ␣B1 was ligated into the vector backbone of CPV2/hGH, replacing the ␣A-crystallin promoter to create ␣B1/hGH.
The ␣A/␣B4/hGH construct was made through several steps. First, the 3Ј untranslated region and polyadenylation signal of the murine ␣B-crystallin gene was amplified by PCR and ligated into the large fragment of the ␣B1 vector, replacing the SV40-derived intron and polyadenylation sequence of ␣B1. This intermediate plasmid was called ␣B2. The first intron of the murine ␣B-crystallin gene was amplified by PCR and inserted into the ␣B1 vector, creating the intermediate vector ␣B3. A three-way ligation with the ␣B-crystallin promoter and first intron from ␣B3, the hGH gene from pOGH, 43 and the ␣B-crystallin 3Ј untranslated region-polyadenylation sequences and plasmid backbone of ␣B2 created ␣B4/hGH. To generate the composite ␣A/␣B promoter, CPV7 (described earlier) was digested with BglII and BamHI to remove the Ϫ86/ϩ43 region of the ␣A-crystallin gene. The PCR-amplified murine ␣B-crystallin promoter (described earlier) was digested with BglII and ligated into the BglII/ BamHI-cut CPV7, creating the intermediate ␣A/␣B composite promoter vector. The ␣A/␣B composite promoter was then used to replace the ␣B-crystallin promoter of ␣B4/hGH, completing the ␣A/ ␣B4/hGH construct.
The Cre coding sequence and intron-polyadenylation sequences contained in the murine metallothionein gene were excised from pBS216 (obtained from Brian Sauer, Stowers Institute, Kansas City, MO 2 ) and ligated into HindIII/SalI cut CPV14 and CPV2, creating CPV14/Cre and CPV2/Cre, respectively.
Generation of Transgenic Mice
All animals were treated in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Microinjection fragments were isolated from CPV2/hGH, CPV14/hGH, CPV15/hGH, ␣B1/hGH, TYBS (a tyrosinase minigene), 45 ␣A/␣B4/hGH, CPV14/Cre, and CPV2/Cre following digestion with appropriate restriction enzymes and gel purification with a gel extraction kit (QiaexII; Qiagen, Hilden, Germany). All microinjection constructs were injected into pronuclear stage FVB/N mouse embryos as described. 46 All hGH transgenic constructs were injected independently, but Cre constructs were either injected independently or coinjected with the TYBS cassette. 45 
Histology, Immunohistochemistry, and In Situ Hybridization
Eyes or embryos were collected and fixed in 4% paraformaldehyde, processed, and embedded in paraffin. Embedded samples were sectioned at 5 m. Immunohistochemical staining for hGH was performed as described previously. 43 An hGH-specific riboprobe vector, CB4, was created by ligating the 3Ј untranslated region of the human growth hormone gene from the pSW2 47 vector (obtained from Lewis T. Williams, University of California, San Francisco) into pBluescript II KS(Ϫ) (Stratagene, La Jolla, CA). Antisense [
35 S]-UTP-labeled probes were synthesized using a HindIII-digested CB4 template and T7 RNA polymerase (Promega, Madison, WI). In situ hybridization of tissue sections was performed as described previously.
42
X-Gal Staining for ␤-Galactosidase Activity
To evaluate the expression pattern of the Cre transgene, Cre transgenic mouse lines were crossed with a homozygous ROSA26 reporter line (B6;129S-Gtrosa26 tm1Sor ). 48 Mouse embryos, neonatal eyes and lens epithelium from mice at weaning age were collected and analyzed for ␤-galactosidase activity by x-gal staining, as described. 42 
RESULTS
Characterization of Engineered ␣-Crystallin Promoters
We produced several transgenic constructs in which an hGH reporter gene was placed under the regulatory control of modified versions of the murine ␣A-crystallin promoter or a short fragment (Ϫ214/ϩ38) of the murine ␣B-crystallin promoter ( Table 1 ). The activity of these promoters was initially tested by using a transient transgenic approach in which transgenic founder embryos were collected at 15.5 days after coitus (embryonic day [E]15.5). At least two transgenic founder embryos were generated for each construct and evaluated for hGH expression by both in situ hybridization and immunohistochemistry.
CPV2/hGH consisted of the hGH reporter gene downstream of the (Ϫ282/ϩ43) murine ␣A-crystallin promoter (Fig. 1A , Table 1 ). The ␣B1/hGH construct was identical to CPV2/hGH except that the ␣A-crystallin promoter was replaced with a short fragment (Ϫ214/ϩ38) of the murine ␣B-crystallin promoter (Fig. 1A , Table 1 ). A composite promoter including the Ϫ282/Ϫ86 region of the murine ␣A-crystallin promoter followed by the Ϫ214/ϩ38 promoter fragment and the first intron of murine ␣B-crystallin gene was also created. The hGH Of three founder embryos carrying the ␣B1/hGH transgene, only one (33%) showed evidence of reporter gene expression. The Ϫ214/ϩ38 region of the ␣B-crystallin promoter directed hGH expression in this founder embryo to the lens epithelium Transgenic constructs with the ␣-crystallin promoter fragments used to drive the expression of an hGH reporter gene. The CPV2/hGH construct contained the Ϫ282/ϩ43 murine ␣A-crystallin promoter (heavily stippled box) driving hGH (filled box). The ␣B1/hGH differed from CPV2/hGH only by the replacement of the murine ␣A-crystallin promoter with the Ϫ214/ϩ38 ␣B-crystallin promoter (open box). The ␣A/␣B4/ hGH construct contained a chimeric promoter consisting of the Ϫ282/Ϫ86 fragment of the murine ␣A-crystallin promoter (heavily stippled box) fused to the Ϫ214/ϩ38 murine ␣B-crystallin promoter (open box). The chimeric promoter was followed by the first intron of the murine ␣B-crystallin gene (striped box). The 3Ј untranslated region of the murine ␣B-crystallin cDNA (checkered box) followed the stop codon for hGH in this construct. and RPE with very little detectable expression in lens fiber cells (Figs. 1F-I ). Three stable transgenic lines were generated with the ␣B1/hGH construct (OVE1046, OVE1047, and OVE1048). Of these lines, two (OVE1046 and OVE1048) demonstrated transgene expression in the lens epithelial cells, RPE, and developing ciliary body in E15.5 embryos. One line (OVE1046) expressed the reporter gene weakly in the lens fiber cells (data not shown). Overall, three (50%) of the six transgenic founders or lines made with the ␣B1/hGH construct expressed the transgene in the lens. In an attempt to increase the level of lens transgene expression in the ␣B1/hGH founders, we created a chimeric promoter consisting of the Ϫ282/Ϫ86 fragment of the mouse ␣A-crystallin promoter fused to the Ϫ214/ϩ38 mouse ␣B1-promoter, intron 1 of ␣B-crystallin, and the 3Ј untranslated sequence. Of the five ␣A/␣B4/hGH transgenic founder embryos, reporter gene expression was found in three (60%). In these founders, hGH was detected in the lens epithelium and RPE. In one (20%) founder, patchy expression in the corneal epithelium was detected by in situ hybridization, but not by immunohistochemistry (Figs. 1J-M) . None of the ␣A/␣B4/hGH founder embryos expressed the transgene in the lens fiber cells. Thus, despite its activity in the lens epithelium, the ␣A/␣B4 chimeric promoter failed to activate transgene expression in the lens fibers, indicating the Ϫ282/Ϫ86 ␣A-crystallin promoter fragment was insufficient to activate transgene expression in the lens fibers when coupled with the Ϫ214/ϩ38 ␣B-crystallin promoter.
Effect of Insertion of the Pax6 Consensus Binding Site into the ␣A-crystallin Promoter on Transgene Expression in the Lens Epithelium
The differential expression patterns of ␣A-and ␣B-crystallins within the lens and the observation that Pax6 directly regulates expression of ␣B-crystallin in the lens epithelium prompted us to hypothesize that we might be able to enhance the activity of the murine ␣A-crystallin promoter in the lens epithelium by incorporating additional Pax6-binding regulatory elements. To test this hypothesis, we made a small modification in CPV2 by inserting a 32-bp sequence containing a Pax6 consensus binding site in either orientation, creating CPV14 and CPV15, respectively. The insertion site is located at Ϫ86 (relative to the transcription start site) of the ␣A-crystallin gene, a region devoid of elements known to be important for ␣A-crystallin transcriptional regulation. The hGH gene was then subcloned into both of these vectors, creating CPV14/hGH and CPV15/ hGH ( Fig. 2A, Table 1 ).
Transgenic mice made with either CPV14/hGH or CPV15/ hGH constructs expressed hGH mRNA and protein specifically in both the lens epithelium and fibers (Figs. 2B-I ). Because both CPV14/hGH and CPV15/hGH supported transgene expression in the lens epithelium, the inclusion of the Pax6 consensus binding sequence in the Ϫ282/ϩ43 region of ␣A-crystallin promoter enhanced lens epithelial transgene expression in an orientation-independent manner. In these transgenic founder embryos, no ocular expression of the hGH reporter gene was detected outside the lens.
Generation of CPV2/Cre and CPV14/Cre Transgenic Mice
Because hGH expression driven by both the CPV14 and CPV15 promoters was specific to the lens and detected in both the lens epithelium and fiber cells in transgenic founder embryos, we decided to test the activity of the CPV14 promoter more thoroughly by using a different reporter gene. To this end, we cloned Cre recombinase into CPV2 and CPV14, creating CPV2/ Cre and CPV14/Cre constructs, respectively. In these constructs, the mouse metallothionein gene is downstream of the Cre coding sequence, providing introns and a polyadenylation signal (Table 1) . In most cases, a tyrosinase minigene cassette was coinjected with the Cre transgenes to facilitate identification of transgenic animals by coat color. 45 Seven transgenic lines were established for each Cre transgene construct. Lines coinjected with tyrosinase minigene were also transgenic for this marker ( Table 2 ). The expression 
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of Cre in these transgenic lines was tested by crossing the transgenic mice to a ROSA26 reporter mouse strain in which LacZ expression is dependent on Cre-mediated recombination. 48 Once Cre-mediated recombination occurs in a given cell, that cell and all its descendants will express LacZ. Therefore, tissues that stained blue with x-gal-marked cell lineages in which Cre had been present and active.
The results of these analyses are shown in Figure 3 and summarized in Table 2 . Of the seven CPV14/Cre transgenic lines, four lines (57%) showed evidence of LacZ expression in most lens epithelial cells in addition to the lens fibers, demonstrating enhanced lens epithelial activity of the CPV14 promoter (Figs. 3A-D, 3AЈ-DЈ). Two lines (29%) demonstrated incomplete epithelial activity while maintaining extensive reporter expression in the fiber cells (Figs. 3E, 3EЈ, 3F, 3FЈ ). In the remaining transgenic line (14%), LacZ expression was limited in both the lens epithelium and fibers (Figs. 3G, 3GЈ ). In our experience, the lack of blue staining in the deeper fiber cells represents a failure of staining reagents to diffuse deep into the intact lens, but not the absence of Cre expression in the embryonic fiber cells. These results contrasted sharply with those obtained from the CPV2/Cre transgenic lines. In four transgenic lines (57%), abundant LacZ reporter expression was detected in the lens fibers, but was largely absent from the lens epithelium (Figs. 3H-K, 3HЈ-3KЈ; Table 2 ). One transgenic line (14%) showed sparse LacZ expression in the lens epithelial cells, despite extensive activity in the lens fibers (Figs. 3L, 3LЈ ). In the remaining two transgenic lines (29%), LacZ expression was limited in both the lens epithelium and fiber cells (Figs. 3M, 3MЈ, 3N, 3NЈ) . Therefore, the insertion of this Pax6 consensus binding site expanded the expression domain of the ␣A-crystallin promoter to most of the lens epithelium. It is noteworthy that the majority of the Cre transgenic lines (11/12 lines, 92%) that were also transgenic for the coinjected tyrosinase minigene cassette, ocular expression of LacZ was not restricted to the lens. These ectopic sites of ocular transgene expression included retina, RPE, and cornea (Table 2) . Whereas in transgenic lines generated without tyrosinase minigene coinjection, reporter gene expression within the eye was limited to the lens (100%, two lines).
The Extent of CPV14 versus CPV2 Promoter Activity in the Lens Epithelium
Though analyses of lens sections indicated the enhanced epithelial activity of CPV14 promoter, it is difficult to evaluate quantitatively the proportion of the entire lens epithelium stained with x-gal in tissue sections. To determine the efficiency of Cre activity in the lens epithelium, we analyzed LacZ reporter expression using wholemount lens epithelial sheets. For the CPV14/Cre construct, the MLR10 and MLR32 lines consistently demonstrated reporter expression in most lens epithelial cells (Figs. 4A, 4B ). In contrast, the MLR39 and MLR37 transgenic lines made from the CPV2/Cre construct, showed little or no LacZ activity in the lens epithelium (Figs.  4C, 4D ). This is consistent with the observed earlier onset of LacZ reporter expression (tested in MLR10) at E10.5 in CPV14/ Cre transgenic mice versus between E11.5 and E12.5 (tested in MLR39) for CPV2 transgenic mice (described later). Overall, though transgene expression driven by the native murine ␣A-crystallin promoter was limited to the lens fiber cells, the addition of the Pax6 consensus binding sequence was capable of influencing the expression pattern of the Ϫ282/ϩ43 murine ␣A-crystallin promoter to include the lens epithelium.
Although the goal of this study was to determine the influence of regulatory elements on transgene expression within the eye, we were also aware that these experiments might generate transgenic lines that could be used to delete genes in lens cells conditionally at different stages of differentiation. Because the utility of these transgenic mice for lens-specific gene deletion depends on the developmental specificity of Cre expression, we evaluated the global pattern of transgene expression in developing embryos. For this purpose, we conducted wholemount x-gal staining of the embryos in several transgenic lines after crossing to the Cre reporter strain. For the CPV14/Cre construct, MLR10, MLR32, and MLR31 embryos were tested (Figs. 5A-C) . MLR39, MLR37, and MLR34 were chosen from transgenic lines made with the CPV2/Cre construct (Figs. 5D-F) . The staining patterns of these transgenic lines were characterized by positive staining in the embryonic lens. Although all transgenic embryos stained with x-gal in the eye, extraocular staining patterns were unique to each transgenic line and varied widely, probably due to different transgene integration sites.
Lines MLR10 from the CPV14/Cre lines and MLR39 from the CPV2/Cre lines emerged as transgenic families in which there was good transgene expression in the lens and minimal extraocular transgene expression. Although no evidence of Cre expression was detected in the lens placode from either MLR10 or MLR39 embryos (data not shown), in MLR10 mice, Cre expression was readily and consistently seen at E10.5 during the lens pit-early lens vesicle stage (Fig. 6A) . Over the next 24 hours, evidence of Cre expression was detectable in The intensity of x-gal staining was visually estimated as being weak (ϩ), medium (ϩϩ), strong (ϩϩϩ) or not detectable (Ϫ).
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the majority of both the lens epithelium and differentiating lens fibers (Fig. 6B) , and this expression expands even more by E12.5 (Fig. 6C) . Although there is some mouse-to-mouse variability, the pattern of expression in the lens is quite consistent.
Occasionally, a few cells in the center of the cornea demonstrate evidence of Cre expression, but we have never seen Cre expression in the neural retina or RPE of MLR10 mice. Outside the eye, MLR10 expression can usually be detected in the snout and vibrissae follicles, as well as in parts of the midbrain and pituitary gland (Fig. 5A) . Very little extraocular expression was detected in MLR39 embryos. Within the MLR39 eye, Cre expression in the RPE was evident by E11.5 (Fig. 6D ), but lens expression of Cre was not evident at this stage. In the MLR39 lens, Cre activity was first evident at E12.5 when most of the fiber cells stain with x-gal (Fig. 6E) . Cre activity was only rarely detected in lens epithelial cells, but most lens cells initiated Cre expression subsequent to a fiber differentiation signal (Figs. 6E,  6F ). Although the MLR39 RPE consistently stained with x-gal, blue-stained cells were not consistently visible in the neural retina (compare Figs. 6D and 6F with 6E).
DISCUSSION
As expected, the Ϫ282/ϩ43 fragment of the murine ␣A-crystallin promoter was effective in driving transgene expression only in lens fiber cells. Therefore, additional distal regulatory elements are likely to be required for the endogenous expression of the murine ␣A-crystallin gene in the lens epithelium. In contrast, the Ϫ214/ϩ38 fragment of the murine ␣B-crystallin promoter consistently directed reporter gene expression to the lens epithelium and RPE and, in all but one case, failed to direct detectable reporter gene expression in the lens fiber cells. This pattern of expression was largely unaltered (with the exception of corneal epithelial expression in one founder) by the addition of the Ϫ282/Ϫ86 ␣A-crystallin promoter fragment and the ␣B-crystallin first intron and polyadenylation sequence. These elements were added to the ␣B-crystallin promoter in an attempt to increase the overall expression level of the transgene, but we reasoned that these modifications (particularly the inclusion of the ␣A-crystallin promoter fragment) might alter promoter specificity. The Ϫ282/Ϫ86 ␣A-crystallin promoter fragment contains a DE1 site Ϫ108/Ϫ100 that has been shown recently to bind c-Maf, a transcription factor essential for lens-specific expression of ␣-, ␤-, and ␥-crystallins 52 , 17 but other regulatory elements of ␣A-crystallin promoter such as the ␣A-CRYBP1 site Ϫ66/Ϫ57, 18, 20, 53 the Pax6 site Ϫ49/Ϫ33 17 , the TATA box -31/Ϫ26, 21 and additional proximal elements at -25/Ϫ12, 21 Ϫ7/ϩ5, 54 and ϩ/24/ϩ43 22, 53 are not included in the composite promoter. Therefore, the DE1 site was insufficient to activate the Ϫ214/ϩ38 ␣B-crystallin promoter in the lens fiber cells, suggesting that the DE1 element must interact with other ␣A-crystallin promoter elements to confer expression in lens fiber cells. Consistent with this interpretation, the Ϫ287/Ϫ85 murine ␣A-crystallin promoter fragment did not work in concert with an SV40 promoter to activate transcription when transfected into lens epithelial explants. 55 In contrast, the insertion of a single copy of a Pax6 consensus binding site in either orientation at Ϫ86, between the DE1 site and the ␣A-CRYBP1 site of murine ␣A-crystallin promoter was able to alter the expression pattern of this promoter independently. During lens development, Pax6 expression exhibits distinct polarity, with higher level expression in the lens epithelium that gradually diminishes during fiber differentiation. 30, 31 In our modified ␣A-crystallin promoter, there are two cis-acting elements that bind Pax6 and stimulate the promoter activity, one from the endogenous ␣A-crystallin promoter Ϫ49/Ϫ33, 17 and the other from the inserted Pax6 consensus binding site. Thus, the insertion of this perfect consensus Pax6 binding site enhanced transgene expression in the lens epithelium without altering the lens specificity of the endogenous ␣A-crystallin promoter sequences. At least two binding sites for Pax6 have been found in the lens epithelium-expressed chicken ␣A-crystallin and ␦-crystallin genes as well as the murine ␣B-crystallin gene, each of which contribute to optimal promoter function. 4, 34, 35 Recent studies indicated that c-Maf could form a complex with the coactivator CBP/p300 to activate the ␣A-crystallin promoter, but Pax6 does not directly interact with this complex. 56 Because c-Maf expression can be upregulated by Pax6, 57 Pax6 can regulate ␣A-crystallin expression both directly and indirectly. The consensus Pax6 binding site inserted into the ␣A-crystallin promoter may recruit additional Pax6, which may act in concert with the c-Maf-CBP/ p300 complex to activate transcription. Previous studies have suggested that Pax6 alone is not sufficient to activate the ␣A-crystallin promoter in the lens, despite the observation that the Ϫ49/Ϫ33 region of murine ␣A-crystallin gene is capable of binding Pax6 and stimulating promoter activity. 17, 58, 59 Mutations in both the DE1 site and ␣A-CRYBP1 site in the Ϫ116/ ϩ46 fragment abolished the function of the ␣A-crystallin promoter in transgenic mice, despite the presence of the native Pax6 binding sequence. 60 The Ϫ96/Ϫ76 region of the murine ␣A-crystallin promoter (where the consensus Pax6 site was inserted) has not been demonstrated to bind nuclear proteins and modulate promoter activity. In addition, replacement of the inserted Pax6 binding site with other cis regulatory elements in the modified murine ␣A-crystallin promoter did not lead to epithelial expression in transgenic mice, indicating that enhanced expression of transgene in the lens epithelium was specific to the Pax6 consensus binding site (Robinson ML, et al. IOVS 1997; 38 :ARVO Abstract 2694). Thus, we think it is unlikely that enhanced epithelial transgene expression resulted from disruption of a negative regulatory element by the Pax6 consensus insertion. The use of different reporters also demonstrated that the influence of the inserted Pax6 binding site was not dependent on particular sequences in the reporter genes. To date, we have not tested the consensus Pax6 site in any other part of the ␣A-crystallin promoter. The reason we used Cre as one of the reporter genes was twofold. In addition to being able to use a Cre reporter line to document Cre activity, we reasoned that the resultant mice might be useful for tissue-specific gene deletion in the lens. In several of the transgenic mice generated, ocular tissues other than the lens stained positively for x-gal in eyes of both CPV2/ Cre and CPV14/Cre transgenic mice. Ocular Cre expression outside the lens was not seen in the transgenic lines where the tyrosinase minigene was absent. Therefore, we think that it is likely that the tyrosinase minigene was able to influence the activity of the coinjected CPV2 and CPV14 promoters within the eye. Transgene expression outside the eye varied considerably from line to line and was probably the result of integration site-specific effects.
Transgenic lines MLR10 and MLR39 demonstrated different patterns of Cre expression within the lens and reasonably little extraocular Cre expression, and we believe that these mice represent potentially useful tools for conditional gene deletion experiments in the lens. Absolute tissue specificity is a rare characteristic of Cre-expressing transgenic mouse lines, and the usefulness of any particular Cre line must be evaluated in the context of the question being asked and the normal expression pattern of the gene one desires to delete.
During the course of these studies, others independently generated the LeCre transgenic mouse line. 32 In the LeCre mice, the Pax6 P0 promoter, including the upstream ectoderm enhancer, was used to drive expression of Cre recombinase to the lens placode. Cre recombinase expression in the LeCre mice starts at the lens placode stage, making these mice particularly useful for deleting genes during early lens development. Cre expression at this early stage also explains the lack of lens specificity for the LeCre line, as the Cre-expressing tissue also gives rise to the corneal epithelium, conjunctiva and part of the eyelid. 32 Like the transgenic mice we describe in this report, the LeCre mice do not exhibit complete ocular specificity of Cre expression. LeCre mice consistently express the Cre transgene in the developing pancreas. Cre expression in our best CPV14/Cre transgenic line (MLR10) initiates during the lens pit stage and is detectable in most lens cells at the lens vesicle stage when lens fiber cell differentiation commences. Therefore, MLR10 may be useful in the study of lens fiber differentiation, provided the limited extraocular Cre expression does not interfere with embryonic survival or with the development of tissues that indirectly influence the eye. We anticipate that conditional targeting of genes with different Cre transgenic lines will provide valuable functional information on specific genes at different stages of lens development.
